Anagrelide 500microgram capsules
Requires a prescription from a doctor or prescriber
Anagrelide is a platelet-reducing agent used to lower dangerously elevated platelet levels (i.e.
Official documents, adverse reaction reporting, and safety monitoring
Report a side effect
Submit a Yellow Card report to the MHRA
Official medicine documents
Safety monitoring data
Yellow Card reports
The MHRA Yellow Card scheme collects reports of suspected side effects from healthcare professionals and patients. View the Drug Analysis Profile (iDAP) for real-world adverse reaction data.
View Drug Analysis Profile
Suspected adverse reactions reported for Anagrelide
Browse all iDAP reports
Interactive Drug Analysis Profiles for all medicines
Report a side effect
Submit a Yellow Card report to the MHRA
Data from the MHRA Yellow Card scheme. A reported reaction does not necessarily mean the medicine caused it. Contains public sector information licensed under the Open Government Licence v3.0.
EudraVigilance
The European Medicines Agency (EMA) collects suspected adverse reaction reports from across the EU/EEA through the EudraVigilance system. Search for safety data on this medicine.
View EudraVigilance report
Suspected adverse reactions reported for Anagrelide
About EudraVigilance
Learn about EU pharmacovigilance and safety monitoring
EudraVigilance data is published by the European Medicines Agency (EMA). A suspected adverse reaction is not necessarily caused by the medicine.
20 branded products available
MHRA licensed products
View all licensed products for Anagrelide on the MHRA register
Xagrid 500microgram capsules
Xagrid 500microgram capsules
Anagrelide 500microgram capsules
Anagrelide 500microgram capsules
Anagrelide 500microgram capsules
Anagrelide 500microgram capsules
Anagrelide 500microgram capsules
Anagrelide 500microgram capsules
Anagrelide 500microgram capsules
Anagrelide 500microgram capsules
Anagrelide 500microgram capsules
This is the NHS Drug Tariff indicative price used for reimbursement purposes. It may not reflect the price paid by patients or pharmacies.
View full Drug TariffSource: NHS Drug Tariff via NHSBSA. Derived from dm+d VMPP (Virtual Medicinal Product Pack) pricing data. Contains public sector information licensed under the Open Government Licence v3.0.
Therapeutically similar medicines
Similarity is based on WHO Anatomical Therapeutic Chemical (ATC) classification and on a factual NHS dm+d therapeutic-grouping code prefix. Source data: NHS dm+d via TRUD (OGL v3.0), WHO ATC/DDD Index.
NHS prescribing volume and spending trends
Guidelines from the National Institute for Health and Care Excellence
NICE clinical guidance(2)
Ruxolitinib for treating polycythaemia vera (TA921)
Momelotinib for treating myelofibrosis-related splenomegaly or symptoms (TA957)
Source: National Institute for Health and Care Excellence (NICE). Contains public sector information licensed under the Open Government Licence v3.0.
Check stock at pharmacies and supply information
Pharmacy stock checkers
Search for this medicine at major UK pharmacy chains. These links open the retailer's own website — results depend on their current online catalogue.
Supply & safety information
Official UK regulator monitoring and safety alerts
Pharmacy links redirect to the retailer's own search and do not represent real-time stock levels. Shortage and safety information sourced from MHRA drug safety updates (gov.uk, Crown Copyright under OGL v3.0).
Codes for healthcare professionals and prescribing systems
These codes are used by healthcare IT systems and prescribers to identify this medicine.
NHS UK identifiers
Browse tools
SNOMED CT and dm+d codes from NHS TRUD (Technology Reference data Update Distribution), licensed under the Open Government Licence v3.0. BNF code shown is the factual mapping value distributed by NHS Business Services Authority (NHSBSA) in the dm+d supplementary file under OGL v3.0; it is not affiliated with, nor licensed from, the publishers of the British National Formulary. ATC codes from the WHO Collaborating Centre for Drug Statistics Methodology (whocc.no).
Active and completed clinical studies from ClinicalTrials.gov
Source: ClinicalTrials.gov, a database of the U.S. National Library of Medicine (NLM), National Institutes of Health (NIH). Data accessed via ClinicalTrials.gov API v2. Trial information is provided for research purposes and does not constitute medical advice.
Academic studies and reviews for this medicine's active substance
Showing the 50 most relevant studies.
Reviews & meta-analyses: 11 · Randomised trials: 3 · 1988–2026
Showing the 50 most relevant studies, sorted by most relevant.
Heinz Gisslinger, Mirjana Gotić, Jerzy Hołowiecki, et al.
Blood, 2013
Abreu Lopez B, Arvelaez Pascucci J, Ramzy SM, et al.
2025
- Quinazolines
- Platelet Aggregation Inhibitors
- Thrombocythemia, Essential
M. I. A. Abdel Maksoud, Gharieb S. El‐Sayyad, A. H. Ashour, et al.
Materials Science and Engineering C, 2018
Claire Harrison, Peter J. Campbell, Georgina Buck, et al.
New England Journal of Medicine, 2005
- Antineoplastic Agents
- Aspirin
- Hemorrhage
The American Journal of Medicine, 1992
- Clinical Protocols
- Hydroxyurea
- Platelet Aggregation Inhibitors
Bethany Samuelson Bannow, Chatree Chai‐Adisaksopha, David García
Journal of Thrombosis and Thrombolysis, 2015
- Hemorrhage
- Hydroxyurea
- Quinazolines
H. Gisslinger, V. Buxhofer-Ausch, Juri Hodisch, et al.
British Journal of Haematology, 2019
R. Mesa, N. Komatsu, H. Gill, et al.
Blood, 2021
Elizabeth C. Storen, Ayalew Tefferi
Blood, 2001
- Hemorrhage
- Platelet Aggregation Inhibitors
- Quinazolines
Murray N. Silverstein, Robert M. Petitt, Lawrence A. Solberg, et al.
New England Journal of Medicine, 1988
- Hematopoietic Stem Cells
- Myeloproliferative Disorders
- Platelet Aggregation Inhibitors
Sources: aggregated from Europe PMC (EMBL-EBI), OpenAlex, Crossref, PubMed and other open scholarly databases. Retracted articles are excluded. Study information is provided for research purposes and does not constitute medical advice.
Pharmacology and chemical data from DrugBank
Key facts
Drug status
Approved
Major interactions
44 found
Half-life
1.5 hours
Mechanism
The exact mechanism by which anagrelide lowers platelet count is unclear.
Food interactions
1 warning
Human targets
1 target
Data: DrugBank · CC BY-NC 4.0
Pharmacokinetics at a glance
Absorption
70%
[L14153]…
Half-life
1.5 hours
[L14153]
Metabolism
Elimination
1%
Pharmacokinetic data: DrugBank · CC BY-NC 4.0
[L14153]
Known interactions with other medications. Always consult a healthcare professional.
Showing 50 of 1200 interactions
[L14243]
Symptoms of overdose may include hypotension, sinus tachycardia, and vomiting. As the therapeutic effect of anagrelide (i.e. platelet reduction) is dose-related, significant thrombocytopenia is expected in instances of overdose.
[L14153]
Treatment of overdose should involve careful monitoring of platelet counts and complications such as bleeding.
[L14153]
Employ symptomatic and supportive measures if clinically indicated.
Anagrelide is a known inhibitor of phosphodiesterase 3A (PDE3A), although its platelet-lowering effects appear unrelated to this inhibition.[A204317] While PDE3 inhibitors, as a class, can inhibit platelet aggregation, this effect is only seen at higher anagrelide doses (i.e. greater than those required to reduce platelet count).[L14153] Modulation of PDE3A has been implicated in causing cell cycle arrest and apoptosis in cancer cells expressing both PDE3A and SLFN12,[A204167] and may be of value in the treatment of gastrointestinal stromal tumours.[A204314]
Evidence from animal studies suggests anagrelide may impair female fertility.[L14153] Female patients of reproductive age should be advised of the potential for adverse effects on fertility prior to initiating therapy.
How the body processes this drug — absorption, distribution, metabolism, and elimination
[L14153]
Given on an empty stomach, the Cmax is reached within 1 hour (Tmax) of administration. Co-administration with food slightly lowers the Cmax and increases the AUC, but not to a clinically significant extent.
[L14153]
[L14153]
[L14153]
[L14153]
Proteins and enzymes this drug interacts with in the body
PMID:1315035 PMID:25961942 PMID:8155697 PMID:8695850
Also has activity toward cUMP .
PMID:27975297
Independently of its catalytic activity it is part of an E2/17beta-estradiol-induced pro-apoptotic signaling pathway. E2 stabilizes the PDE3A/SLFN12 complex in the cytosol, promoting the dephosphorylation of SLFN12 and activating its pro-apoptotic ribosomal RNA/rRNA ribonuclease activity. This apoptotic pathway might be relevant in tissues with high concentration of E2 and be for instance involved in placenta remodeling PMID:31420216 PMID:34707099
Enzymes involved in drug metabolism — important for understanding drug interactions
ATC L01XX35
Chemical identifiers
CAS, UNII, InChI Key and database cross-references
Show
Chemical identifiers
CAS, UNII, InChI Key and database cross-references
Linked compound data from DrugBank Open Data (CC BY-NC 4.0)
Anagrelide
Additional database identifiers
Drugs Product Database (DPD)
11707
ChemSpider
2097
BindingDB
50000334
PDB
J33
ZINC
ZINC000003871541
HUGO Gene Nomenclature Committee (HGNC)
HGNC:8778
GenAtlas
PDE3A
GeneCards
PDE3A
GenBank Gene Database
M91667
GenBank Protein Database
38201493
Guide to Pharmacology
1298
UniProt Accession
PDE3A_HUMAN
HUGO Gene Nomenclature Committee (HGNC)
HGNC:2596
GenAtlas
CYP1A2
GeneCards
CYP1A2
GenBank Gene Database
Z00036
Guide to Pharmacology
1319
UniProt Accession
CP1A2_HUMAN
DrugBank citations
If you use DrugBank data in your research, please cite the following publications:
Show earlier publications
Structured knowledge from the free knowledge base
ATC classifications (Wikidata)
Linked open data from Wikidata (Q408163), a free and open knowledge base operated by the Wikimedia Foundation. Data is available under the Creative Commons CC0 1.0 Public Domain Dedication. WHO INN from the World Health Organization.